Aldeyra Shares Rally After AbbVie Licensing Deal on Eye Drug
By Rob Curran Aldeyra Therapeutics shares rose after the development-stage biotech company struck a licensing deal with drug giant AbbVie on an eye-condition...
Stay updated with breaking news from Aldx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Rob Curran Aldeyra Therapeutics shares rose after the development-stage biotech company struck a licensing deal with drug giant AbbVie on an eye-condition...
Health-care companies rose, but not by as much as the broad market, amid mixed earnings reports. Shares of drug-store chain and insurer CVS Health fell after...
Aldeyra Therapeutics, Inc (NASDAQ:ALDX – Get Free Report) major shareholder Perceptive Advisors Llc sold 2,450,000 shares of Aldeyra Therapeutics stock in a transaction on Monday, October 16th. The stock was sold at an average price of $1.60, for a total value of $3,920,000.00. Following the completion of the transaction, the insider now owns 8,900,085 shares […]
Aldeyra Therapeutics, Inc. (ALDX) shares are falling more than 58 percent on Monday morning trade after the company announced that the FDA, in a review related to its new drug application for Reproxalap for dry eye disease, opined that the data is not supporting the clinical relevance of the ocular signs to support dry eye indication.
Shares of Aldeyra Therapeutics Inc. plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq’s decliners,...